Aclaris Therapeutics (NASDAQ:ACRS) Announces Earnings Results

Aclaris Therapeutics (NASDAQ:ACRS) issued its earnings results on Thursday. The biotechnology company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.04, FiscalAI reports. The company had revenue of $1.48 million for the quarter, compared to the consensus estimate of $1.27 million. Aclaris Therapeutics had a negative net margin of 921.50% and a negative return on equity of 61.65%.

Aclaris Therapeutics Price Performance

Shares of NASDAQ ACRS traded up $0.21 during mid-day trading on Friday, hitting $3.83. 1,780,568 shares of the company’s stock traded hands, compared to its average volume of 2,219,873. The company has a market capitalization of $534.81 million, a P/E ratio of -6.59 and a beta of 0.96. Aclaris Therapeutics has a 1 year low of $2.10 and a 1 year high of $6.60. The company’s 50-day moving average is $4.67 and its two-hundred day moving average is $4.54.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on ACRS shares. Craig Hallum set a $9.00 price objective on Aclaris Therapeutics in a report on Wednesday, October 28th. Canaccord Genuity Group lifted their price target on Aclaris Therapeutics from $10.00 to $13.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Monday, September 21st. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Aclaris Therapeutics in a report on Wednesday, October 28th. Finally, Wedbush lowered their target price on shares of Aclaris Therapeutics from $10.00 to $8.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 28th. Three investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $11.33.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company focused on developing therapies for immune-inflammatory diseases. The company’s research programs are designed to address conditions in areas such as rheumatology, dermatology and other inflammatory disorders.

Aclaris’ lead investigational product is zunsemetinib (ATI-450), an oral small-molecule therapy being evaluated for inflammatory diseases. The company has also developed additional investigational programs, including selective kinase inhibitors intended for potential use in dermatologic and immune-mediated conditions.